# Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR

> **NCT00567359** · PHASE2 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 100 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT00567359
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2017-12
- **Final completion:** 2017-12
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2018-12-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00567359

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00567359, "Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT00567359. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*